Erber Ramona, Hartmann Arndt
Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Breast Care (Basel). 2020 Aug;15(4):327-336. doi: 10.1159/000509025. Epub 2020 Jul 15.
Invasive breast cancer (IBC) can be categorized into prognostic and predictive molecular subtypes (including luminal breast cancer) using gene expression profiling. Luminal IBC comprises a variety of histological subtypes with varying clinical and pathological features.
IBC of no special subtype is the most common histological subtype in general and likewise within luminal IBC. Classical invasive lobular breast cancer, typically clustering into luminal subgroup, is characterized by discohesive growth and loss of E-cadherin expression. Infrequent, morphologically distinct luminal IBC subtypes are tubular, invasive cribriform, mucinous, and invasive micropapillary carcinomas. Breast carcinoma with apocrine differentiation, with characteristic expression of androgen receptor (AR), often clusters into the luminal AR category. Rarely, neuroendocrine neoplasms of the breast can be seen. IBC of the male breast usually matches with the luminal subtype.
Independently from histological subtypes, invasive breast cancer (IBC) can be divided into molecular subtypes based on mRNA gene expression levels. Using this molecular subtyping, risk scores based on gene expression profiling (established for hormone receptor-positive, HER2-negative IBC), grading, and Ki-67 index, prognosis of patients with luminal breast cancer and response to chemotherapy can be predicted. In routine diagnostics, the expression of estrogen receptor (ER) and progesterone receptor (PR), HER2 status, and the proliferation rate (Ki-67) are used to determine a surrogate (molecular-like) subtype. Within luminal(-like) IBC, no special subtype and invasive lobular breast carcinoma are the most common histological subtypes. Other rare histological subtypes (e.g., tubular carcinoma) should be recognized due to their distinct clinical and pathological features.
浸润性乳腺癌(IBC)可通过基因表达谱分析分为预后和预测分子亚型(包括管腔型乳腺癌)。管腔型IBC包含多种具有不同临床和病理特征的组织学亚型。
非特殊亚型的IBC是一般情况下最常见的组织学亚型,在管腔型IBC中也是如此。经典浸润性小叶癌通常聚集在管腔亚组中,其特征是细胞间黏附丧失和E-钙黏蛋白表达缺失。少见的、形态学上不同的管腔型IBC亚型包括管状癌、浸润性筛状癌、黏液癌和浸润性微乳头状癌。具有顶泌汗腺分化的乳腺癌,具有雄激素受体(AR)的特征性表达,通常聚集在管腔AR类别中。很少能见到乳腺神经内分泌肿瘤。男性乳腺的IBC通常与管腔型亚型相符。
独立于组织学亚型之外,浸润性乳腺癌(IBC)可根据mRNA基因表达水平分为分子亚型。利用这种分子分型,基于基因表达谱(针对激素受体阳性、HER2阴性IBC建立)、分级和Ki-67指数的风险评分,可以预测管腔型乳腺癌患者的预后和对化疗的反应。在常规诊断中,雌激素受体(ER)和孕激素受体(PR)的表达、HER2状态以及增殖率(Ki-67)用于确定替代(分子样)亚型。在管腔样IBC中,非特殊亚型和浸润性小叶癌是最常见的组织学亚型。其他罕见的组织学亚型(如管状癌)因其独特的临床和病理特征应予以识别。